Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission.

@article{Vclavk2010DevelopmentOL,
  title={Development of L{\"o}ffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission.},
  author={Jan V{\'a}clav{\'i}k and Tom{\'a}{\vs} Szotkowski and Martin Hutyra and Jiř{\'i} Koz{\'a}k and Jan Lukl and Milo{\vs} T{\'a}borsk{\'y}},
  journal={American journal of hematology},
  year={2010},
  volume={85 4},
  pages={296-9}
}
summary Acute myelogenous leukemia (AML) associated with core binding factor (CBF) abnormalities is sensitive to high-dose cytarabine-based chemotherapy leading to complete remission (CR) in over 90% of patients. The efficacy of cytarabine can be enhanced by the addition of fludarabine and GCSF with report of improved event free survival with this regimen… CONTINUE READING